Quantitative assessment of the reproducibility of functional activation measured with BOLD and MR perfusion imaging: implications for clinical trial design.

BOLD contrast is the most commonly used functional MRI method for studies of brain activity. However, the underlying physiological processes giving rise to measured BOLD signal changes (which include contribution from changes in cerebral blood flow (CBF), cerebral blood volume (CBV) and cerebral met...

Повний опис

Бібліографічні деталі
Автори: Tjandra, T, Brooks, J, Figueiredo, P, Wise, R, Matthews, P, Tracey, I
Формат: Journal article
Мова:English
Опубліковано: 2005
_version_ 1826268388224139264
author Tjandra, T
Brooks, J
Figueiredo, P
Wise, R
Matthews, P
Tracey, I
author_facet Tjandra, T
Brooks, J
Figueiredo, P
Wise, R
Matthews, P
Tracey, I
author_sort Tjandra, T
collection OXFORD
description BOLD contrast is the most commonly used functional MRI method for studies of brain activity. However, the underlying physiological processes giving rise to measured BOLD signal changes (which include contribution from changes in cerebral blood flow (CBF), cerebral blood volume (CBV) and cerebral metabolic rate of oxygen consumption (CMRO2)) vary substantially between sessions and subjects. To determine whether direct CBF measurement is a more reliable technique, we compared the localisation of activation and reproducibility of relative signal change measured by optimised BOLD versus CBF measured using the arterial spin labelling (ASL) technique. Data were collected within the primary sensorimotor cortex in normal healthy controls performing a simple finger-tapping task over three imaging sessions (two on same day and one on a different day). The displacement between the foci of BOLD and CBF activation was less than the linear dimension of one voxel (2.4 mm), however, BOLD activation was significantly closer to the nearest draining vein compared to CBF activation (P=0.030). For the relative signal change measurement, we found that CBF has a lower inter-subject variation than BOLD (P<0.05), enabling a smaller sample size for any given effect size, although the intra-subject variation across sessions for CBF was not significantly different from BOLD. BOLD imaging provides the optimal contrast for exploratory brain activation mapping, however, for a single time-point group study, CBF has reduced variance. In addition, the reduction of variance over time using CBF measurements (non-significant) suggests it could potentially provide a more useful approach when assessing longitudinal activation changes.
first_indexed 2024-03-06T21:08:55Z
format Journal article
id oxford-uuid:3d78a2c6-df7e-459b-a30d-ead645a5b964
institution University of Oxford
language English
last_indexed 2024-03-06T21:08:55Z
publishDate 2005
record_format dspace
spelling oxford-uuid:3d78a2c6-df7e-459b-a30d-ead645a5b9642022-03-26T14:19:30ZQuantitative assessment of the reproducibility of functional activation measured with BOLD and MR perfusion imaging: implications for clinical trial design.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:3d78a2c6-df7e-459b-a30d-ead645a5b964EnglishSymplectic Elements at Oxford2005Tjandra, TBrooks, JFigueiredo, PWise, RMatthews, PTracey, IBOLD contrast is the most commonly used functional MRI method for studies of brain activity. However, the underlying physiological processes giving rise to measured BOLD signal changes (which include contribution from changes in cerebral blood flow (CBF), cerebral blood volume (CBV) and cerebral metabolic rate of oxygen consumption (CMRO2)) vary substantially between sessions and subjects. To determine whether direct CBF measurement is a more reliable technique, we compared the localisation of activation and reproducibility of relative signal change measured by optimised BOLD versus CBF measured using the arterial spin labelling (ASL) technique. Data were collected within the primary sensorimotor cortex in normal healthy controls performing a simple finger-tapping task over three imaging sessions (two on same day and one on a different day). The displacement between the foci of BOLD and CBF activation was less than the linear dimension of one voxel (2.4 mm), however, BOLD activation was significantly closer to the nearest draining vein compared to CBF activation (P=0.030). For the relative signal change measurement, we found that CBF has a lower inter-subject variation than BOLD (P<0.05), enabling a smaller sample size for any given effect size, although the intra-subject variation across sessions for CBF was not significantly different from BOLD. BOLD imaging provides the optimal contrast for exploratory brain activation mapping, however, for a single time-point group study, CBF has reduced variance. In addition, the reduction of variance over time using CBF measurements (non-significant) suggests it could potentially provide a more useful approach when assessing longitudinal activation changes.
spellingShingle Tjandra, T
Brooks, J
Figueiredo, P
Wise, R
Matthews, P
Tracey, I
Quantitative assessment of the reproducibility of functional activation measured with BOLD and MR perfusion imaging: implications for clinical trial design.
title Quantitative assessment of the reproducibility of functional activation measured with BOLD and MR perfusion imaging: implications for clinical trial design.
title_full Quantitative assessment of the reproducibility of functional activation measured with BOLD and MR perfusion imaging: implications for clinical trial design.
title_fullStr Quantitative assessment of the reproducibility of functional activation measured with BOLD and MR perfusion imaging: implications for clinical trial design.
title_full_unstemmed Quantitative assessment of the reproducibility of functional activation measured with BOLD and MR perfusion imaging: implications for clinical trial design.
title_short Quantitative assessment of the reproducibility of functional activation measured with BOLD and MR perfusion imaging: implications for clinical trial design.
title_sort quantitative assessment of the reproducibility of functional activation measured with bold and mr perfusion imaging implications for clinical trial design
work_keys_str_mv AT tjandrat quantitativeassessmentofthereproducibilityoffunctionalactivationmeasuredwithboldandmrperfusionimagingimplicationsforclinicaltrialdesign
AT brooksj quantitativeassessmentofthereproducibilityoffunctionalactivationmeasuredwithboldandmrperfusionimagingimplicationsforclinicaltrialdesign
AT figueiredop quantitativeassessmentofthereproducibilityoffunctionalactivationmeasuredwithboldandmrperfusionimagingimplicationsforclinicaltrialdesign
AT wiser quantitativeassessmentofthereproducibilityoffunctionalactivationmeasuredwithboldandmrperfusionimagingimplicationsforclinicaltrialdesign
AT matthewsp quantitativeassessmentofthereproducibilityoffunctionalactivationmeasuredwithboldandmrperfusionimagingimplicationsforclinicaltrialdesign
AT traceyi quantitativeassessmentofthereproducibilityoffunctionalactivationmeasuredwithboldandmrperfusionimagingimplicationsforclinicaltrialdesign